COXFA4L2
ENSG00000185633
Target class
Enzyme
Chromosome
12
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- COXFA4L2
- Gene name
- Cytochrome c oxidase hypoxia associated subunit FA4L2
- Gene symbol
- COXFA4L2
- Previous gene symbols
- NDUFA4L2
- Protein name
- Cytochrome c oxidase hypoxia associated subunit FA4L2 (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4-like 2) (NADH-ubiquinone oxidoreductase MLRQ subunit homolog) (NUOMS)
- NUOMS
- FLJ26118
- MISTRH
- Gene biotype
- Protein coding
- Gene family
- Mitochondrial complex IV: cytochrome c oxidase subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 199.81
- Tissue specificity (Gini)
- 0.527
- Tissue specificity (tau)
- 0.817
- KEGG gene identifiers
- hsa:56901
- Protein interaction confidence
- 0.790455
- Protein interaction partners
- 33
- End position
- 57240715
- Start position
- 57234903
- Chromosome
- 12
- Strand
- Reverse
- Mitochondrion inner membrane
- Single-pass membrane protein .
- Mitochondria
Publication evidence
- PubMed 22100406
- Tissue specificity (tau)
- 0.816985
- Expression inequality (Gini)
- 0.526802
Expression in transcripts per million
- Artery - Tibial
- 199.81
- Artery - Coronary
- 168.76
- Esophagus - Mucosa
- 165.55
- Skin - Not Sun Exposed (Suprapubic)
- 142.1
- Skin - Sun Exposed (Lower leg)
- 135.55
Expression in transcripts per million
- Artery - Tibial199.81
- Artery - Coronary168.76
- Esophagus - Mucosa165.55
- Skin - Not Sun Exposed (Suprapubic)142.1
- Skin - Sun Exposed (Lower leg)135.55
- Vagina114.79
- Artery - Aorta112.29
- Adipose - Subcutaneous67.94
- Adipose - Visceral (Omentum)59.38
- Thyroid54.6
- Spleen50.3
- Lung48.62
- Nerve - Tibial43.98
- Heart - Atrial Appendage43.27
- Heart - Left Ventricle40.82
- Breast - Mammary Tissue39.21
- Kidney - Medulla37.79
- Brain - Cerebellum33.69
- Brain - Cerebellar Hemisphere29
- Pituitary27.94
- Esophagus - Muscularis27.73
- Brain - Substantia nigra26.29
- Brain - Putamen (basal ganglia)26.26
- Cervix - Ectocervix24.94
- Uterus24.68
And 29 more, listed on the interactive page.
- GO:0001666
- GO:0071456
- GO:1902957
Cellular components
- GO:0005739
Molecular functions
- GO:0004857
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor